GET DAILY SIGNALSCingulate (CING) Shares Advance +14.7% in 30 Days as NDA Resubmission Nears
Key Takeaways
- Cingulate (CING) shares advanced roughly 14.7% over the trailing 30 days, rising from about $4.82 to $5.53.
- The stock pulled back into mid-October before staging a sharp late-month rebound, highlighting its elevated volatility.
- Over the trailing quarter, CING is up roughly 22%, supported by progress toward a New Drug Application (NDA) resubmission for lead ADHD candidate CTx-1301.
- The FDA's Complete Response Letter centered on chemistry, manufacturing, and controls (CMC) items rather than clinical safety or efficacy.
- A strengthened balance sheet, with a cash runway into mid-2027, remains a central focus for investors.
Cingulate (CING) Company Overview and Market Position
Cingulate Inc. is a clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, focused on developing next-generation treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. Its core technology is the proprietary Precision Timed Release (PTR) drug delivery platform, which is designed to release medication in controlled pulses at specific times throughout the day.
The company's lead asset is CTx-1301 (dexmethylphenidate hydrochloride), a once-daily, multi-core tablet intended to provide rapid onset and sustained symptom control across a patient's active day. Because CING is pre-revenue, its valuation is driven primarily by regulatory progress, intellectual property, financing, and commercial-readiness milestones rather than current sales or earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cingulate (CING) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, CING shares climbed about 14.7%, moving from a closing level near $4.82 in late September to roughly $5.53. The move was not a straight line: the stock declined through early-to-mid October, touching an intraday low around $4.12 before rebounding sharply in the final sessions of the period.
The quarterly picture is stronger but equally volatile. Over the last three months, the stock has gained roughly 22%, rising from about $4.53 to $5.53. The quarter included a late-August peak near $5.87, a subsequent retracement, and a late-October recovery. This pattern reflects the binary, sentiment-driven nature typical of clinical-stage biotechnology equities awaiting regulatory decisions. From what I see, these swings underscore the importance of monitoring key catalysts closely.
What Drove CING Stock Price in the Last 30 Days
The 30-day period was defined by a pullback into mid-October followed by a pronounced late-month rebound. No single disclosed announcement coincided with the recovery's final leg, but the backdrop included several company-specific fundamentals that shaped investor positioning.
Cingulate continues to work with its manufacturing partner to complete the CMC work requested in the FDA's Complete Response Letter for CTx-1301, with the goal of resubmitting the NDA. The letter did not raise clinical safety or efficacy concerns, which has kept the regulatory story focused on execution rather than the drug's effectiveness. The company has also reported a cash position sufficient to fund operations into mid-2027, reducing near-term financing overhang for some investors. These factors, combined with typical small-cap biotech volatility, contributed to the stock's recovery from its October lows.
What Drove CING Stock Performance Over the Last Quarter
The quarter's broader narrative centers on Cingulate's regulatory and operational progress. In June, the company received a Complete Response Letter from the FDA for CTx-1301 that requested additional CMC information while identifying no clinical safety or efficacy concerns. The company subsequently reported second-quarter results and outlined its plan to resubmit the NDA.
Several supporting developments reinforced the investment case during the quarter. Cingulate received its first U.S. patent for CTx-1301, extending exclusivity into late 2042. The company was added to the Russell 3000E Index, potentially broadening institutional visibility. Peer-reviewed and Phase 3 data publications highlighted CTx-1301's differentiated pharmacokinetic profile, and a distribution agreement with Prasco advanced commercial-readiness infrastructure ahead of a potential launch. These milestones, layered on a strengthened balance sheet, shaped the stock's net advance over the period. I'm watching this closely as execution on the resubmission timeline could be pivotal.
CING Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary catalyst for Cingulate remains the CTx-1301 NDA resubmission and the FDA's subsequent response. Investors will also monitor the company's completion of CMC work with its manufacturing partner, updates on commercial-readiness activities, and any additional intellectual-property developments. Balance-sheet management and the pace of cash utilization into mid-2027 are also important considerations, as is broader sentiment toward clinical-stage biotech equities. As with any pre-revenue drug developer, outcomes remain uncertain, and regulatory, financing, and execution risks should be weighed carefully.
Using AI Tools to Analyze Biotech Opportunities
In my view, tools like Tickeron’s AI Trading Bots can provide useful context when evaluating volatile names like CING. I often review their performance metrics alongside traditional analysis to understand how algorithmic strategies are positioned in the sector. This helps highlight potential patterns without replacing fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CING in upward trend: price rose above 50-day moving average on October 26, 2026
CING moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on CING as a result. In 75 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for CING just turned positive on October 23, 2026. Looking at past instances where CING's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +11.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 191 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for CING crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CING broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CING entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.427) is normal, around the industry mean (2.974). P/E Ratio (-1.553) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement